Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 11NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Myeloid 1

Conditions

Neoplasms 1Myelodysplastic Syndromes 1Lymphoma 1Burkitt Lymphoma 1

Interventions

Specimen Handling 354Magnetic Resonance Spectroscopy 252Biopsy 222Nivolumab 69Cyclophosphamide 65Carboplatin 56Radiation 53Paclitaxel 53X-Rays 52pembrolizumab 51Taxes 51Immunoglobulin G 51Disulfides 51Cisplatin 49Platinum 451,2-diaminocyclohexaneplatinum II citrate 45Doxorubicin 44Radiotherapy 42Ipilimumab 38atezolizumab 37fludarabine 35Gemcitabine 35CTLA-4 Antigen 35olaparib 32Vincristine 31Prednisone 31Bevacizumab 30venetoclax 27Cytarabine 27Phantoms, Imaging 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Clofarabine × 1 year × Clear all
NCT02883049 2026-06-02

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

National Cancer Institute (NCI)

Phase 3 Completed
5,949 enrolled 28 charts
Lymphoid

Burkitt Lymphoma

NCT02211755 2026-04-28

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
28 enrolled
LymphoidMyeloid

Lymphoma, Myelodysplastic Syndromes, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡